N. Le and .. Proprement-parlé, 59 3.2.1 L'intégration de l'index et des adaptateurs lors de la PCR 2, ., p.60
URL : https://hal.archives-ouvertes.fr/halshs-00593227

B. , A. Breakpoint-cluster-region, /. Abelson, C. Cytosine, C. Cancer et al., Core Binding Factor ? -Myosin Heavy chain 11 CBL Cluster of Différenciation Comma Separated Value Cycle threshold DNA (cytosine-5)-methyl-transferase 3 alpha DNTP Erythroblastosis virus E26 FMS-like tyrosine kinase, Immunoglobulin Enhancer binding factors E12/E47 (=TCF3).. Flow cell FISH ................... Fluorescence in Situ Hybridization FLT3 GATA binding protein 2

G. Granulocyte, C. Granulocyte-macrophage, C. Group, .. Research-in-adult-acute-lymphoblastic-leukemia-gtpase, H. Guanosine-triphosphate-hydrolase et al., German Multicenter study group for Adult Acute Lymphoblastic Leukemia High Resolution Melting IDH1 et 2, Tyrosine-protein kinase Kit KRAS .................. v-Ki-ras2 Kirsten rat sarcoma viral Leucémie Aigüe Lymphoïde Page

N. Neuroblastoma, R. , O. De-la-santé-pb, and .. , Organisation Mondiale, Peripheric Blood Lymphocytes PBX1 .................. Pre-B cell leukemia transcription factor 1

P. Phosphatase, R. Tensin-homolog, and P. Quantification, Phage X (Illumina) Promyelocytic leukemia-Retinoic acid receptor alpha, Stem Cell Factor SF3B1 ................ Splicing factor 3B subunit 1

S. Myélo-dysplasique, S. Myélo-prolifératif, and S. , Single Molecule Real Time SNP, Single Nucleotide Polymorphism SRSF2 ................ Serine/arginine-Rich Splicing Factor

S. Receptor and T. , Signal Transducer and Activator of Transcription TCF3, Transcription Factor, vol.3, issue.=E2A

R. Bejar, Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.30, issue.27, pp.30-3376, 2012.
DOI : 10.1200/JCO.2011.40.7379

B. Deschler, Acute myeloid leukemia: Epidemiology and etiology, Cancer, vol.9, issue.9, pp.2099-107, 2006.
DOI : 10.1002/cncr.22233

R. M. Stone, Acute Myeloid Leukemia, Hematology, vol.2004, issue.1, pp.98-117, 2004.
DOI : 10.1182/asheducation-2004.1.98

T. Pabst, Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia, Nature Genetics, vol.27, issue.3, pp.263-70, 2001.
DOI : 10.1038/85820

M. Pasquet, High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia., Blood, pp.822-831, 2012.

J. S. Welch, Genomics of AML : Clinical Applications of Next-Generation Sequencing ? Am Soc Hematol, pp.30-35, 2011.

S. H. Swerdlow, WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues - International Agency for Research on cancer, 2008.

D. Grimace, The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties, Blood, vol.92, issue.7, pp.2322-2355, 1998.

A. Melnick, Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia, Blood, vol.93, pp.3167-3215, 1999.

N. A. Speck, Core-binding factor: a central player in hematopoiesis and leukemia Independent prognostic variables in acute myeloid leukaemia. -Blood Rev, Cancer, vol.59, pp.1789-1793, 1999.

M. Krzysztof, Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia ? ASH _ Hematology, 2006.

A. M. Tsimberidou, The role of gemtuzumab ozogamicin in acute leukaemia therapy, British Journal of Haematology, vol.240, issue.0, 2006.
DOI : 10.1038/sj.leu.2402749

M. Nakao, Internal tandem duplication of the flt3 gene found in acute myeloid leukemia, Leukemia, vol.10, issue.12, pp.1911-1919, 1996.

S. Schnittger, Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease, Blood, vol.100, issue.1, pp.59-66, 2002.
DOI : 10.1182/blood.V100.1.59

S. Fröhling, Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm, Blood, vol.100, issue.13, pp.4372-80, 2002.
DOI : 10.1182/blood-2002-05-1440

S. Schnittger, Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype, Blood, vol.106, issue.12, pp.3733-3742, 2005.
DOI : 10.1182/blood-2005-06-2248

K. Dohner, Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations, Blood, vol.106, issue.12, pp.3740-3746, 2005.
DOI : 10.1182/blood-2005-05-2164

C. Thiede, Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML), Blood, vol.107, issue.10, pp.4011-4031, 2006.
DOI : 10.1182/blood-2005-08-3167

T. Pabst, Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome, Nature Genetics, vol.27, issue.3, pp.263-70, 2001.
DOI : 10.1038/85820

T. Pabst, Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis, British Journal of Cancer, vol.18, issue.8, pp.1343-1349, 2009.
DOI : 10.1073/pnas.94.2.569

E. Mardis, Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome, New England Journal of Medicine, vol.361, issue.11, pp.1058-66, 2009.
DOI : 10.1056/NEJMoa0903840

L. Dang, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, vol.50, issue.7274, pp.739-783, 2009.
DOI : 10.1038/nature08617

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818760

T. Ley, Mutations in Acute Myeloid Leukemia, New England Journal of Medicine, vol.363, issue.25, pp.2424-2457, 2010.
DOI : 10.1056/NEJMoa1005143

J. Bennett, Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group, British Journal of Haematology, vol.1, issue.4, pp.451-459, 1976.
DOI : 10.1111/j.1365-2141.1976.tb03563.x

K. Yoshida, Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.451, issue.7367, pp.64-73, 2011.
DOI : 10.1038/nature10496

P. Greenberg, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, vol.89, pp.2079-88, 1997.

A. Maxam and M. , A new method for sequencing DNA., Proceedings of the National Academy of Sciences, vol.74, issue.2, pp.99-103, 1977.
DOI : 10.1073/pnas.74.2.560

F. Sanger and S. Nicklen, DNA sequencing with chain-terminating inhibitors, Proceedings of the National Academy of Sciences, vol.74, issue.12, pp.104-112, 1977.
DOI : 10.1073/pnas.74.12.5463

M. L. Metzker, Sequencing technologies ??? the next generation, Nature Reviews Genetics, vol.37, issue.1, pp.31-46, 2010.
DOI : 10.1038/nrg2626

E. Mardis, Anticipating the 1,000 dollar genome, Genome Biology, vol.7, issue.7, p.112, 2006.
DOI : 10.1186/gb-2006-7-7-112

A. Sboner, The real cost of sequencing: higher than you think!, Genome Biology, vol.12, issue.8, p.125, 2011.
DOI : 10.1186/gm205

T. C. Glenn, Field guide to next-generation DNA sequencers, Molecular Ecology Resources, vol.463, issue.Suppl. 1, pp.759-769, 2011.
DOI : 10.1111/j.1755-0998.2011.03024.x

S. Misale, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.102, issue.7404, pp.532-538, 2012.
DOI : 10.1038/nature11156

A. N. Dessai, Next-generation sequencing: ready for the clinics?, Clinical Genetics, vol.21, issue.5, pp.503-513
DOI : 10.1111/j.1399-0004.2012.01865.x

K. M. Wong and T. J. Hudson, Unraveling the Genetics of Cancer: Genome Sequencing and Beyond, Annual Review of Genomics and Human Genetics, vol.12, issue.1, pp.407-437, 2011.
DOI : 10.1146/annurev-genom-082509-141532

J. Rowley, Chromosomal translocations: revisited yet again, Blood, vol.112, issue.6, pp.2183-2192, 2008.
DOI : 10.1182/blood-2008-04-097931

K. Mrózek, Cytogenetics in acute leukemia, Blood Reviews, vol.18, issue.2, pp.115-151, 2004.
DOI : 10.1016/S0268-960X(03)00040-7

H. Dohner, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-74, 2010.
DOI : 10.1182/blood-2009-07-235358

K. Mrózek, Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.30, issue.36, pp.4515-4538, 2012.
DOI : 10.1200/JCO.2012.43.4738

K. Mrozek, Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia, Hematology, vol.2006, issue.1, pp.169-177, 2006.
DOI : 10.1182/asheducation-2006.1.169

F. Delhommeau, in Myeloid Cancers, New England Journal of Medicine, vol.360, issue.22, pp.2289-301, 2009.
DOI : 10.1056/NEJMoa0810069

R. Bejar, Clinical Effect of Point Mutations in Myelodysplastic Syndromes, New England Journal of Medicine, vol.364, issue.26, pp.2496-506, 2011.
DOI : 10.1056/NEJMoa1013343

M. Jadersten, Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression, Journal of Clinical Oncology, vol.29, issue.15, pp.1971-1980, 2011.
DOI : 10.1200/JCO.2010.31.8576

S. Schnittger, ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome, Leukemia, vol.27, issue.1, 2012.
DOI : 10.1056/NEJMoa1005143

F. Thol, Mutations in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.29, issue.21
DOI : 10.1200/JCO.2011.35.4894

S. Langemeijer, P052 Acquired mutations in TET2 are common in myelodysplastic syndromes, Leukemia Research, vol.33, pp.838-880, 2009.
DOI : 10.1016/S0145-2126(09)70132-8

O. Kosmider, TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs), Blood, vol.114, issue.15, pp.3285-91, 2009.
DOI : 10.1182/blood-2009-04-215814

O. Nibourel, Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML), ASH Annual Meeting Abstracts, vol.114, p.163, 2009.

F. Rücker, TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome, Blood, vol.119, issue.9, pp.2114-2135, 2012.
DOI : 10.1182/blood-2011-08-375758

S. Schnittger, KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival, Blood, vol.107, issue.5, pp.1791-1800, 2006.
DOI : 10.1182/blood-2005-04-1466

R. Cairoli, Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study, Blood, vol.107, issue.9, pp.3463-3471, 2006.
DOI : 10.1182/blood-2005-09-3640

A. Neubauer, Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.26, issue.28, pp.26-4603, 2008.
DOI : 10.1200/JCO.2007.14.0418

A. Neubauer, Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes

S. Jeromin, High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms, Haematologica, vol.98, issue.2, pp.98-113, 2013.
DOI : 10.3324/haematol.2012.072538

C. B. Thompson, Metabolic Enzymes as Oncogenes or Tumor Suppressors, New England Journal of Medicine, vol.360, issue.8, pp.813-818, 2009.
DOI : 10.1056/NEJMe0810213

S. Abbas, Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value, Blood, vol.116, issue.12, pp.116-2122, 2010.
DOI : 10.1182/blood-2009-11-250878

E. Papaemmanuil, Mutation in Myelodysplasia with Ring Sideroblasts, New England Journal of Medicine, vol.365, issue.15, pp.1384-1395, 2011.
DOI : 10.1056/NEJMoa1103283

F. Thol and S. Kade, Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes, Blood, vol.119, issue.15, pp.3578-3584, 2012.
DOI : 10.1182/blood-2011-12-399337

F. Thol, SETBP1 mutation analysis in 944 patients with MDS and AML Leukemia advance online publication, 2013.

S. Schnittger, Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases, Haematologica, vol.97, issue.12, pp.97-1890, 2012.
DOI : 10.3324/haematol.2012.065375

U. Bacher, Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies, Annals of Hematology, vol.24, issue.11 Suppl
DOI : 10.1007/s00277-010-0920-6

T. R. Dreszer, The UCSC Genome Browser database: extensions and updates 2011, Nucleic Acids Research, vol.40, issue.D1, pp.918-923
DOI : 10.1093/nar/gkr1055

E. Abdelhamid, Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia, Leukemia Research, vol.36, issue.3, pp.316-339, 2012.
DOI : 10.1016/j.leukres.2011.11.002

F. Thol, Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations, Genes, Chromosomes and Cancer, vol.99, issue.7, pp.689-95, 2012.
DOI : 10.1002/gcc.21955

D. Wu, High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia, Science Translational Medicine, vol.4, issue.134, pp.134-63, 2012.
DOI : 10.1126/scitranslmed.3003656